Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib vs Bevacizumab with Chemo in 2nd-line mCRC
NCT07051785Phase 2Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07051785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051785.